Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

GEMZAR for Cholangiocarcinoma: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 5 adverse event reports in the FDA FAERS database where GEMZAR was used for Cholangiocarcinoma.

Most Reported Side Effects for GEMZAR

Side Effect Reports % Deaths Hosp.
Malignant neoplasm progression 15 11.3% 6 9
Anaemia 14 10.5% 5 7
Off label use 13 9.8% 2 10
Pleural effusion 13 9.8% 0 8
Pyrexia 13 9.8% 2 9
Interstitial lung disease 12 9.0% 9 9
Decreased appetite 10 7.5% 5 9
Diarrhoea 10 7.5% 2 6
Renal failure acute 10 7.5% 3 9
Lung disorder 9 6.8% 2 4
Thrombocytopenia 9 6.8% 5 5
Vomiting 8 6.0% 2 4
Dyspnoea 7 5.3% 1 4
Metastases to bone 7 5.3% 1 0
Metastases to liver 7 5.3% 2 0

Other Indications for GEMZAR

Pancreatic carcinoma (18) Breast cancer (13) Product used for unknown indication (10) Lung neoplasm malignant (9) Bladder cancer (6) T-cell lymphoma (5)

Other Drugs Used for Cholangiocarcinoma

GEMCITABINE (1,181) CISPLATIN (923) CAPECITABINE (608) DURVALUMAB (444) OXALIPLATIN (441) PEMIGATINIB (431) FLUOROURACIL (341) GEMCITABINE\GEMCITABINE (292) IVOSIDENIB (277) NIVOLUMAB (250)

Related Pages

GEMZAR Full Profile All Cholangiocarcinoma Drugs GEMZAR Demographics GEMZAR Timeline